Literature DB >> 28028559

Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013.

Ja Min Byun1, Young Jin Kim2, Taemi Youk3, John Jeongseok Yang4, Jongha Yoo5, Tae Sung Park6.   

Abstract

Myeloproliferative neoplasms (MPNs), with an expected increment in number, impose substantial economic and social burdens. To this end, we conducted a nationwide population-based descriptive epidemiology study. We also investigated medical cost associated with MPNs. Prevalence was the highest for essential thrombocythemia (ET) (range 4.1-9.0 per 100,000), followed by polycythemia vera (PV) (range 2.8-5.4 per 100,000) and primary myelofibrosis (PMF) (range 0.5-0.9 per 100,000). ET incurred the highest cumulative total cost at US$35 million and the most frequent hospital visits, while PMF incurred the highest average cost per person at US$5000. The mean hemoglobin level was 16.9 ± 2.2 g/dL for PV males and 15.5 ± 2.7 g/dL for PV females. Further analyses on hemoglobin levels showed the true positive rate of PV from the significantly elevated hemoglobin group (defined as >18.5 g/dL for men and >16.5 g/dL for women) was 3.01% and that of MPNs was 3.1%. Here, we provide the biggest population-based report on MPN epidemiology that can readily be used as a representative Asian data.

Entities:  

Keywords:  Asia; Epidemiology; Medical cost; Myeloproliferative neoplasm

Mesh:

Year:  2016        PMID: 28028559     DOI: 10.1007/s00277-016-2902-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.

Authors:  Junshik Hong; Ju Hyun Lee; Ja Min Byun; Ji Yun Lee; Youngil Koh; Dong-Yeop Shin; Jeong-Ok Lee; Sang Mee Hwang; Hyoung Soo Choi; Inho Kim; Sung-Soo Yoon; Soo-Mee Bang
Journal:  Blood Adv       Date:  2019-11-26

2.  The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.

Authors:  Chris Varghese; Tracey Immanuel; Anna Ruskova; Edward Theakston; Maggie L Kalev-Zylinska
Journal:  Curr Oncol       Date:  2021-04-18       Impact factor: 3.677

Review 3.  Recent insights regarding the molecular basis of myeloproliferative neoplasms.

Authors:  Mi-Ae Jang; Chul Won Choi
Journal:  Korean J Intern Med       Date:  2019-11-29       Impact factor: 2.884

4.  Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm.

Authors:  Ik-Chan Song; Sang Hoon Yeon; Myung-Won Lee; Hyewon Ryu; Hyo-Jin Lee; Hwan-Jung Yun; Seon Young Kim; Deog-Yeon Jo
Journal:  Blood Res       Date:  2022-03-31

5.  Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital.

Authors:  Lugyanti Sukrisman
Journal:  J Blood Med       Date:  2022-09-12

Review 6.  The 2020 revision of the guidelines for the management of myeloproliferative neoplasms.

Authors:  Sung-Yong Kim; Sung Hwa Bae; Soo-Mee Bang; Ki-Seong Eom; Junshik Hong; Seongsoo Jang; Chul Won Jung; Hee-Jin Kim; Ho Young Kim; Min Kyoung Kim; Soo-Jeong Kim; Yeung-Chul Mun; Seung-Hyun Nam; Jinny Park; Jong-Ho Won; Chul Won Choi
Journal:  Korean J Intern Med       Date:  2020-12-04       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.